26 February 2021
4basebio UK Societas
(the "Company")
Director’s Dealing
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on
exploiting its intellectual property in the field of gene therapies and DNA
vaccines, announces that, on 25 February 2021, Heikki Lanckriet, chief
executive officer, acquired 3,000 ordinary shares at an average price of 345
pence per share on behalf of persons closely associated with him.
As a result of the acquisition of ordinary shares, Heikki Lanckriet’s
beneficial holding, including shares held by persons closely associated with
him, comprises 1,240,003 ordinary shares representing 10.07 per cent. of the
Company’s issued share capital.
This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014.
For further enquiries, please contact:
4basebio UK Societas Heikki Lanckriet +44 (0)1223 967 943
Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson +44 (0)20 7213 0880
Broker finnCap Ltd Geoff Nash/Richard Chambers/Charlotte Sutcliffe +44 (0)20 7220 0500
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Heikki Lanckriet
2 Reason for notification
a. Position/Status Chief Executive Officer
b. Initial notification/ Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio UK Societas
b. LEI 2138005D5SAG8FIR6G91
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument Identification Code Ordinary Shares ISIN: GB00BLD8ZL39
b. Nature of the transaction Acquisition of ordinary shares
c. Price(s) and volume(s)
Volume(s) Price (p)
1. 1,000 345p 345p 345p
2. 1,000
3. 1,000
d. Aggregated information - Aggregated Volume - Price -3,000 -345 pence per share
e. Date of the transaction 25/2/2021
f. Place of the transaction London Stock Exchange, AIM
Copyright (c) 2021 PR Newswire Association,LLC. All Rights Reserved